Online appendix

Supplementary Figure A. Prevalence of reported statin therapy by treatment group and diabetes status at the time of assessment

Statin use according to treatment group and diabetes diagnosis. Panel A includes data from participants prior to the development of diabetes, including those who did not develop diabetes during follow-up.

Figure B. Hazard ratio associated with statin therapy for developing diabetes by treatment group

Adjusted hazard ratios for developing diabetes were estimated separately for each treatment group from Cox proportional hazards models: **1:** Age, sex, and race/ethnicity; **2:** Model 1 + baseline diabetes risk factors (family hx of diabetes, fasting plasma glucose, log insulinogenic index, log 1/fasting insulin), waist); **3:** Model 2 + time dependent statin confounders (use of

antihypertensive medications, diastolic blood pressure, systolic blood pressure, HDL cholesterol, and LDL cholesterol) which were updated until visit prior to statin initiation or diabetes assessment, plus baseline SES (years of education and household income) and reported history of cardiovascular disease at baseline; **4:** Model 2+ time dependent diabetes risk factors (log 1/fasting insulin, log insulinogenic index, waist) updated until the visit prior to the assessment of diabetes; **5:** Model 3 + updated diabetes risk factors.